Merck & Co., Inc 8-K, filed Oct 29, 2026

Merck & Co., Inc. (MRK)

8-K 2026-10-29 For: 2026-10-29

Added on October 29, 2026

About this 8-K

Merck & Co., Inc filed this 8-K on October 29, 2026.

Merck & Co., Inc. reported third-quarter 2026 sales of $18.1 billion (5% Growth; 4% Growth ex-FX), GAAP EPS of $2.04 and non-GAAP EPS of $2.49. It raised full-year sales outlook to $66.8 billion–$67.3 billion and non-GAAP EPS outlook to $2.77–$2.82. AI summary

Items reported

Item 2.02: Financial results
Item 9.01: Financial statements and exhibits

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Common Stock ($0.50 par value)	MRK	New York Stock Exchange
3.250% Notes due 2032	MRK/32	New York Stock Exchange
2.500% Notes due 2034	MRK/34	New York Stock Exchange
1.375% Notes due 2036	MRK 36A	New York Stock Exchange
3.500% Notes due 2037	MRK/37	New York Stock Exchange
3.700% Notes due 2044	MRK/44	New York Stock Exchange
3.750% Notes due 2054	MRK/54	New York Stock Exchange

Exhibit 99.1	Press release issued October 29, 2026, regarding earnings for the third quarter of 2026

Exhibit 99.2	Certain supplemental information not included in the press release

Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

		Merck & Co., Inc.

Date: October 29, 2026	By:	/s/ Kelly E. W. Grez
		Kelly E. W. Grez
		Corporate Secretary

	Third Quarter
$ in millions, except EPS amounts	2026		2025		Change			Change Ex- Exchange
Sales	$	18,085	$	17,276		5	%		4	%
GAAP net income²		5,065		5,785		-12	%		-14	%
Non-GAAP net income that excludes certain items^2,3*		6,159		6,448		-4	%		-5	%
GAAP EPS		2.04		2.32		-12	%		-13	%
Non-GAAP EPS that excludes certain items^3*		2.49		2.58		-3	%		-5	%

	Third Quarter
$ in millions	2026		2025		Change			Change Ex- Exchange			Commentary
Total Sales	$	18,085	$	17,276		5	%		4	%
Pharmaceutical		16,268		15,611		4	%		4	%	Increase primarily driven by growth in KEYTRUDA/KEYTRUDA QLEX, WINREVAIR, GARDASIL/GARDASIL 9, WELIREG, ENFLONSIA and the inclusion of OHTUVAYRE sales. Growth benefited from the timing of purchases by approximately $550 million. Growth was partially offset by declines in BRIDION, JANUVIA/JANUMET and LAGEVRIO, as well as lower alliance revenue related to Koselugo.
KEYTRUDA/ KEYTRUDA QLEX		8,601		8,147		6	%		6	%	Growth primarily driven by strong global uptake in earlier-stage indications including triple-negative breast cancer, cervical cancer, head and neck cancer and bladder cancer, as well as higher global demand in metastatic indications, including urothelial cancer. Timing of wholesaler purchases unfavorably affected sales in the U.S. but was largely offset by a benefit from increased inventory in the channel. Sales of KEYTRUDA QLEX were $830 million.
GARDASIL/GARDASIL 9		1,995		1,749		14	%		14	%	Increase primarily due to higher sales in the U.S. reflecting favorable public-sector purchasing patterns and higher net pricing.
PROQUAD, M-M-R II and VARIVAX		730		684		7	%		7	%	Increase primarily due to higher demand in certain European markets.
WINREVAIR		694		360		93	%		94	%	Growth primarily reflects higher demand and favorable wholesaler and specialty pharmacy purchasing patterns in the U.S., as well as launch uptake in certain international markets, particularly in Europe and Japan.
JANUVIA/JANUMET		380		624		-39	%		-39	%	Decline primarily driven by lower demand due to generic competition following loss of market exclusivity in the U.S.
Lynparza*		352		379		-7	%		-7	%	Decline primarily due to lower net pricing in the U.S. and lower demand and pricing in China.
PREVYMIS		347		266		30	%		31	%	Increase primarily due to higher demand globally.

$ in millions	GAAP			Acquisition- and Divestiture- Related Costs⁴		Restructuring Costs		(Income) Loss From Investments in Equity Securities			Non- GAAP³
Third Quarter 2026
Cost of sales	$	4,892		$	1,140	$	396	$	-		$	3,356
Selling, general and administrative		2,886			24		-		-			2,862
Research and development		4,537			3		1		-			4,533
Restructuring costs		184			-		184		-			-
Other (income) expense, net		27			-		-		(393	)		420

Third Quarter 2025
Cost of sales	$	3,855		$	621	$	110	$	-		$	3,124
Selling, general and administrative		2,633			34		-		-			2,599
Research and development		4,234			4		233		-			3,997
Restructuring costs		47			-		47		-			-
Other (income) expense, net		(238	)		-		-		(344	)		106

	o	Ifinatamab deruxtecan (I-DXd) Biologics License Application (BLA), in collaboration with Daiichi Sankyo, for certain patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) was voluntarily withdrawn.

	§	U.S. FDA set a PDUFA date for both sNDAs of April 22, 2027.

	§	In HYPERION, in patients diagnosed with PAH in the last 12 months, adding WINREVAIR on top of background therapy reduced the risk of clinical worsening events compared to placebo.

	o	Presented results from Phase 2b study of tulisokibart in adults with moderate to severe hidradenitis suppurativa (HS).

	o	At the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in October, presented for the first time one-year results from Phase 2b/3 BRUNELLO trial evaluating remigromig, an investigational, tetravalent, tri-specific antibody designed to agonize the Wingless-related integration site (Wnt) pathway, in adults with diabetic macular edema (DME).

Oncology	Sac-TMT Reduced Risk of Death by 32% and Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer; Results From Phase 3 TroFuse-005 Trial
	The Company and Moderna Presented Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Plus KEYTRUDA at ESMO 2026 Presidential Symposium; Intismeran Plus KEYTRUDA Significantly Reduced Risk of Recurrence or Death by 42% (HR=0.58 [95% CI, 0.45–0.75]; Two-Sided p<0.001) Compared to KEYTRUDA Alone for Patients With Completely Resected Stage IIB-IV Melanoma
	KEYTRUDA as Monotherapy Reduced Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With dMMR Tumors Compared to Chemotherapy; Results From Phase 3 KEYNOTE-C93 Trial
	U.S. FDA Approved WELIREG Plus Lenvima for Certain Previously Treated Adult Patients With ccRCC; Based on Results From Phase 3 LITESPARK-011 Trial, Presented at ESMO

	KEYTRUDA QLEX Approved in Japan for Subcutaneous Administration for All KEYTRUDA Indications Approved in Japan; Based on Results From Phase 3 MK-3475A-D77 Trial
	EC Approved KEYTRUDA Plus Padcev as Perioperative Treatment for Adults With Resectable MIBC; Based on Results From Phase 3 KEYNOTE-B15 Trial
	I-DXd BLA for Certain Patients With ES-SCLC Voluntarily Withdrawn
	The Company Entered Into Exclusive Global License Agreement With SciBrunch for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Vaccines and Infectious Diseases	U.S. FDA Accepted sBLA for ENFLONSIA to Update Its RSV LRTD Indication to Include Children Under 2 Years at Increased Risk for Severe RSV for Their Second Season; Based on Results From Phase 3 SMART Trial; FDA Set PDUFA Date of March 22, 2027
Cardiometabolic, Respiratory and Specialty	U.S. FDA Approved Update to the Label for WINREVAIR to Include Data From the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed With PAH (PAH, WHO Group 1 Pulmonary Hypertension)
Immunology	Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe HS
Ophthalmology	The Company Presented One-Year Results From Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-Specific Agonist of the Wnt Pathway, in Adults With DME, at AAO 2026

	Full Year 2026
	Updated	Prior
Sales^*	$66.8 billion to $67.3 billion	$66.3 billion to $67.3 billion
Non-GAAP Gross margin³	Approximately 81%	Approximately 81%
Non-GAAP Operating expenses^3**	$42.4 billion to $42.9 billion	$42.0 billion to $42.7 billion
Non-GAAP Other (income) expense, net³	Approximately $1.4 billion expense	Approximately $1.4 billion expense
Non-GAAP Effective income tax rate³	32.0% to 33.0%	35.0% to 36.0%
Non-GAAP EPS^3***	$2.77 to $2.82	$2.66 to $2.76
Share count (assuming dilution)	Approximately 2.48 billion	Approximately 2.48 billion

	News Release

	GAAP								GAAP
		3Q26			3Q25		% Change			Sep YTD 2026			Sep YTD 2025		% Change
Sales	$	18,085		$	17,276		5	%	$	50,978		$	48,611		5	%

Costs, Expenses and Other
Cost of sales		4,892			3,855		27	%		13,482			10,831		24	%
Selling, general and administrative		2,886			2,633		10	%		8,491			7,835		8	%
Research and development		4,537			4,234		7	%		26,871			11,903		*
Restructuring costs		184			47		*			530			676		-22	%
Other (income) expense, net		27			(238	)	*			262			(281	)	*
Income Before Taxes		5,559			6,745		-18	%		1,342			17,647		-92	%
Income Tax Provision		492			958					1,855			2,346
Net Income (Loss)		5,067			5,787		-12	%		(513	)		15,301		*
Less: Net Income (Loss) Attributable to Noncontrolling Interests		2			2					(3	)		10
Net Income (Loss) Attributable to Merck & Co., Inc., Rahway, N.J., USA	$	5,065		$	5,785		-12	%	$	(510	)	$	15,291		*

Earnings (Loss) per Common Share Assuming Dilution ⁽¹⁾	$	2.04		$	2.32		-12	%	$	(0.21	)	$	6.08		*

Average Shares Outstanding Assuming Dilution ⁽¹⁾		2,478			2,498					2,471			2,514
Effective Income Tax Rate		8.9	%		14.2	%				138.2	%		13.3	%

	GAAP			Acquisition- and Divestiture-Related Costs⁽¹⁾		Restructuring Costs⁽²⁾		(Income) Loss from Investments in Equity Securities		Adjustment Subtotal		Non-GAAP
Third Quarter
Cost of sales	$	4,892		1,140		396				1,536		$	3,356
Selling, general and administrative		2,886		24						24			2,862
Research and development		4,537		3		1				4			4,533
Restructuring costs		184				184				184			–
Other (income) expense, net		27						(393	)	(393	)		420
Income Before Taxes		5,559		(1,167	)	(581	)	393		(1,355	)		6,914
Income Tax Provision (Benefit)		492		(239	)⁽³⁾	(105	)⁽³⁾	83	⁽³⁾	(261	)		753
Net Income		5,067		(928	)	(476	)	310		(1,094	)		6,161
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA		5,065		(928	)	(476	)	310		(1,094	)		6,159
Earnings per Common Share Assuming Dilution	$	2.04		(0.38	)	(0.19	)	0.12		(0.45	)	$	2.49

Effective Income Tax Rate		8.9	%										10.9	%

September YTD
Cost of sales	$	13,482		3,221		817				4,038		$	9,444
Selling, general and administrative		8,491		73						73			8,418
Research and development		26,871		9		34				43			26,828
Restructuring costs		530				530				530			–
Other (income) expense, net		262						(764	)	(764	)		1,026
Income Before Taxes		1,342		(3,303	)	(1,381	)	764		(3,920	)		5,262
Income Tax Provision (Benefit)		1,855		(660	)⁽³⁾	(240	)⁽³⁾	163	⁽³⁾	(737	)		2,592
Net (Loss) Income		(513	)	(2,643	)	(1,141	)	601		(3,183	)		2,670
Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA		(510	)	(2,643	)	(1,141	)	601		(3,183	)		2,673
(Loss) Earnings per Common Share Assuming Dilution ⁽⁴⁾	$	(0.21	)	(1.07	)	(0.46	)	0.24		(1.29	)	$	1.08

Effective Income Tax Rate		138.2	%										49.3	%

		2026								2025											3Q		Sep YTD
		1Q		2Q		3Q		Sep YTD		1Q		2Q		3Q		Sep YTD		4Q		Full Year	Nom %	Ex-Exch %	Nom %	Ex-Exch %
TOTAL SALES ⁽¹⁾	$	16,286	$	16,607	$	18,085	$	50,978	$	15,529	$	15,806	$	17,276	$	48,611	$	16,400	$	65,011	5	4	5	4
PHARMACEUTICAL		14,349		14,760		16,268		45,377		13,638		14,050		15,611		43,299		14,843		58,142	4	4	5	4
Oncology
Keytruda		7,906		7,904		7,771		23,581		7,205		7,956		8,142		23,303		8,337		31,641	-5	-4	1	0
Keytruda Qlex		128		463		830		1,420						5		5		35		40	*	*	*	*
Alliance Revenue – Lynparza ⁽²⁾		341		365		352		1,059		312		370		379		1,061		389		1,450	-7	-7	0	-2
Alliance Revenue – Lenvima ⁽²⁾		256		283		287		826		258		265		258		781		272		1,053	11	11	6	5
Welireg		199		271		307		776		137		162		196		496		220		716	56	58	57	57
Alliance Revenue – Reblozyl ⁽³⁾		148		122		177		448		119		107		136		361		164		525	31	31	24	24
Vaccines & Infectious Diseases
Gardasil/Gardasil 9		1,069		1,169		1,995		4,232		1,327		1,126		1,749		4,202		1,031		5,233	14	14	1	0
ProQuad/M-M-R II/Varivax		538		592		730		1,860		539		609		684		1,832		619		2,451	7	7	2	1
Bridion		472		497		144		1,113		441		461		439		1,341		499		1,841	-67	-67	-17	-17
Prevymis		272		295		347		915		208		228		266		702		275		978	30	31	30	29
Capvaxive		142		184		263		588		107		129		244		480		279		759	8	7	22	22
Vaxneuvance		202		148		195		545		230		229		226		685		140		825	-14	-13	-20	-22
RotaTeq		206		134		196		536		228		121		204		554		119		673	-4	-4	-3	-4
Zerbaxa		82		77		90		249		70		74		81		225		87		312	11	11	11	9
Delstrigo		75		101		67		243		67		83		77		228		79		306	-13	-12	7	3
Enflonsia		1		2		187		190						79		79		21		100	138	136	142	140
Isentress/Isentress HD		59		60		52		171		90		86		82		258		67		325	-36	-36	-34	-34
Dificid		34		22		14		70		83		96		43		222		25		247	-68	-68	-68	-68
Lagevrio		28		5		17		49		102		83		138		323		57		380	-88	-88	-85	-85
Cardiometabolic, Respiratory, & Specialty
Winrevair		525		588		694		1,808		280		336		360		976		467		1,443	93	94	85	85
Januvia		367		258		186		811		549		372		382		1,302		302		1,604	-51	-50	-38	-37
Janumet		207		171		194		572		247		251		243		741		199		940	-20	-20	-23	-24
Ohtuvayre		131		204		184		519										178		178	-	-	-	-
Alliance Revenue - Adempas/Verquvo ⁽⁴⁾		109		126		118		353		106		123		112		340		129		470	5	5	4	4
Adempas ⁽⁵⁾		78		78		78		234		68		80		82		229		83		312	-5	-3	2	-1
Other Pharmaceutical ⁽⁶⁾		774		641		793		2,209		865		703		1,004		2,573		770		3,340	-21	-21	-14	-15
ANIMAL HEALTH		1,791		1,775		1,676		5,243		1,588		1,646		1,615		4,849		1,505		6,354	4	3	8	5
Livestock		1,064		1,041		1,048		3,154		924		961		1,023		2,909		987		3,896	2	2	8	5
Companion Animal		727		734		628		2,089		664		685		592		1,940		518		2,458	6	6	8	5
Other Revenues ⁽⁷⁾		146		72		141		358		303		110		50		463		52		515	185	-25	-23	-8

	2026												2025																		% Change
		1Q			2Q			3Q			Sep YTD			1Q			2Q			3Q			Sep YTD			4Q			Full Year		3Q		Sep YTD
Sales	$	16,286		$	16,607		$	18,085		$	50,978		$	15,529		$	15,806		$	17,276		$	48,611		$	16,400		$	65,011		5	%	5	%

Costs, Expenses and Other
Cost of sales		4,195			4,395			4,892			13,482			3,419			3,557			3,855			10,831			5,551			16,382		27	%	24	%
Selling, general and administrative		2,700			2,904			2,886			8,491			2,552			2,649			2,633			7,835			2,898			10,733		10	%	8	%
Research and development		12,592			9,741			4,537			26,871			3,621			4,048			4,234			11,903			3,886			15,789		7	%	*
Restructuring costs		195			151			184			530			69			560			47			676			213			889		*		-22	%
Other (income) expense, net		138			99			27			262			(35	)		(7	)		(238	)		(281	)		432			151		*		*
(Loss) Income Before Taxes		(3,534	)		(683	)		5,559			1,342			5,903			4,999			6,745			17,647			3,420			21,067		-18	%	-92	%
Income Tax Provision		709			654			492			1,855			818			571			958			2,346			458			2,804
Net (Loss) Income		(4,243	)		(1,337	)		5,067			(513	)		5,085			4,428			5,787			15,301			2,962			18,263		-12	%	*
Less: Net (Loss) Income Attributable to Noncontrolling Interests		(3	)		(2	)		2			(3	)		6			1			2			10			(1	)		9
Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA	$	(4,240	)	$	(1,335	)	$	5,065		$	(510	)	$	5,079		$	4,427		$	5,785		$	15,291		$	2,963		$	18,254		-12	%	*

(Loss) Earnings per Common Share Assuming Dilution ⁽¹⁾	$	(1.72	)	$	(0.54	)	$	2.04		$	(0.21	)	$	2.01		$	1.76		$	2.32		$	6.08		$	1.19		$	7.28		-12	%	*

Average Shares Outstanding Assuming Dilution ⁽¹⁾		2,472			2,470			2,478			2,471			2,531			2,513			2,498			2,514			2,488			2,507
Effective Income Tax Rate		-20.1	%		-95.9	%		8.9	%		138.2	%		13.9	%		11.4	%		14.2	%		13.3	%		13.4	%		13.3	%

	GAAP			Acquisition- and Divestiture-Related Costs ⁽¹⁾			Restructuring Costs ⁽²⁾			(Income) Loss from Investments in Equity Securities			Certain Other Items			Adjustment Subtotal			Non-GAAP
Third Quarter
Cost of sales	$	3,855			621			110									731		$	3,124
Selling, general and administrative		2,633			34												34			2,599
Research and development		4,234			4			233									237			3,997
Restructuring costs		47						47									47			–
Other (income) expense, net		(238	)								(344	)					(344	)		106
Income Before Taxes		6,745			(659	)		(390	)		344						(705	)		7,450
Income Tax Provision (Benefit)		958			(119	)⁽³⁾		(82	)⁽³⁾		73	⁽³⁾		86	⁽⁴⁾		(42	)		1,000
Net Income		5,787			(540	)		(308	)		271			(86	)		(663	)		6,450
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA		5,785			(540	)		(308	)		271			(86	)		(663	)		6,448
Earnings per Common Share Assuming Dilution	$	2.32			(0.22	)		(0.12	)		0.11			(0.03	)		(0.26	)	$	2.58

Effective Income Tax Rate		14.2	%																	13.4	%

September YTD
Cost of sales	$	10,831			1,817			311									2,128		$	8,703
Selling, general and administrative		7,835			72			1									73			7,762
Research and development		11,903			14			286									300			11,603
Restructuring costs		676						676									676			–
Other (income) expense, net		(281	)		(3	)					(512	)					(515	)		234
Income Before Taxes		17,647			(1,900	)		(1,274	)		512						(2,662	)		20,309
Income Tax Provision (Benefit)		2,346			(338	)⁽³⁾		(239	)⁽³⁾		109	⁽³⁾		(60	)⁽⁴⁾		(528	)		2,874
Net Income		15,301			(1,562	)		(1,035	)		403			60			(2,134	)		17,435
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA		15,291			(1,562	)		(1,035	)		403			60			(2,134	)		17,425
Earnings per Common Share Assuming Dilution	$	6.08			(0.62	)		(0.41	)		0.16			0.02			(0.85	)	$	6.93

Effective Income Tax Rate		13.3	%																	14.2	%

	Global						U.S.						International
	3Q 2026		3Q 2025		% Change		3Q 2026		3Q 2025		% Change		3Q 2026		3Q 2025		% Change
TOTAL SALES ⁽¹⁾	$	18,085	$	17,276		5	$	10,615	$	10,012		6	$	7,471	$	7,264		3
PHARMACEUTICAL		16,268		15,611		4		10,119		9,493		7		6,149		6,118		1
Oncology
Keytruda		7,771		8,142		-5		4,520		4,879		-7		3,251		3,263		0
Keytruda Qlex		830		5		*		693		5		*		136				-
Alliance Revenue – Lynparza ⁽²⁾		352		379		-7		171		184		-7		182		195		-7
Welireg		307		196		56		237		161		47		69		35		96
Alliance Revenue – Lenvima ⁽²⁾		287		258		11		204		177		15		83		81		3
Alliance Revenue – Reblozyl ⁽³⁾		177		136		31		145		111		31		33		25		31
Vaccines & Infectious Diseases
Gardasil/Gardasil 9		1,995		1,749		14		1,366		1,154		18		629		595		6
ProQuad/M-M-R II/Varivax		730		684		7		561		554		1		169		130		30
Prevymis		347		266		30		189		128		48		158		138		14
Capvaxive		263		244		8		207		238		-13		55		7		*
RotaTeq		196		204		-4		150		141		6		46		63		-28
Vaxneuvance		195		226		-14		111		134		-18		85		91		-7
Enflonsia		187		79		138		141		78		80		45				-
Bridion		144		439		-67		108		392		-72		36		47		-24
Zerbaxa		90		81		11		56		49		15		34		32		6
Delstrigo		67		77		-13		13		13		-3		54		64		-15
Isentress/Isentress HD		52		82		-36		31		44		-31		21		37		-43
Lagevrio		17		138		-88		7		24		-71		10		114		-91
Dificid		14		43		-68		7		30		-78		7		13		-44
Cardiometabolic, Respiratory, & Specialty
Winrevair		694		360		93		610		335		82		84		25		*
Janumet		194		243		-20		61		78		-22		133		165		-19
Januvia		186		382		-51		78		258		-70		108		124		-12
Ohtuvayre		184				-		184				-
Alliance Revenue - Adempas/Verquvo ⁽⁴⁾		118		112		5		108		103		4		10		8		20
Adempas ⁽⁵⁾		78		82		-5								78		82		-5
Other Pharmaceutical ⁽⁶⁾		793		1,004		-21		161		223		-28		633		784		-19
ANIMAL HEALTH		1,676		1,615		4		493		504		-2		1,184		1,112		6
Livestock		1,048		1,023		2		199		213		-7		850		811		5
Companion Animal		628		592		6		294		291		1		334		301		11
Other Revenues ⁽⁷⁾		141		50		185		3		15		-80		138		34		*

		3Q26			3Q25			Sep YTD 2026			Sep YTD 2025
Interest income	$	(52	)	$	(96	)	$	(122	)	$	(274	)
Interest expense		546			327			1,550			946
Exchange losses		63			56			138			224
Income from investments in equity securities, net ⁽¹⁾		(401	)		(373	)		(811	)		(563	)
Net periodic defined benefit plan (credit) cost other than service cost		(120	)		(152	)		(382	)		(452	)
Other, net		(9	)		-			(111	)		(162	)
Total	$	27		$	(238	)	$	262		$	(281	)